Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
Authors
Antoine Thiery-Vuillemin
University Hospital Jean Minjoz, Besançon, France
Antoine Thiery-Vuillemin , Philippe Barthelemy , Thierry Lebret , Pierre Bigot , Ulrich Stein , Louis Marie Dourthe , Raffaele Longo , Jeannine De La Cruz , Sandra Sevaux , Malka Tindel , Laurence Albiges , Bernard Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 299)
DOI
10.1200/JCO.2022.40.6_suppl.299
Abstract #
299
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu
Poster
2017 ASCO Annual Meeting
Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.
First Author: Georg A. Bjarnason
Poster
2017 Genitourinary Cancers Symposium
The SUNPAZ study: Results of an open label, single arm trial to evaluate patients with mRCC treated with everolimus after failure of first line therapy with sunitinib or pazopanib.
First Author: Martin Schostak
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst